Eli Lilly Gains Retail Interest Amid Weight-Loss Market Growth
Eli Lilly attracts strong retail interest as the weight-loss market expands, even after Novo Nordisk's setback. Explore LLY's market position now.
Topic
LLY
A collection of 6 issues
Eli Lilly Surges on Zepbound Sleep Apnea Drug Approval
Eli Lilly's stock climbs as Zepbound becomes the first FDA-approved treatment for sleep apnea, boosting investor confidence and market position.
Eli Lilly Surges on FDA Nod for Zepbound
Eli Lilly shares rise as FDA approves Zepbound for weight-loss, aiding sleep apnea. Discover the impact on LLY stock and market trends.
Eli Lilly's Zepbound Gains FDA Approval for Sleep Apnea
Eli Lilly's Zepbound secures FDA approval, becoming the first drug to treat sleep apnea in obese adults, shaking up the device market.
Eli Lilly's Zepbound Approval Boosts Stock
Eli Lilly's shares rise 1.6% after FDA approval of Zepbound for sleep apnea, marking a 34% increase YTD. Explore Eli Lilly's success in the weight-loss market.
Eli Lilly's Market Cap Soars $170B with Zepbound Demand
Eli Lilly's market cap surged by $170 billion as demand for its obesity drug, Zepbound, positions it as a leader in the obesity drug market. Discover the impact.